BARCELONA, Spain -- An antiplatelet-anticoagulant duo, which showed promise in treating coronary disease, increased the risk of life-threatening bleeding events in patients with peripheral arterial disease, according to results of a trial reported here.
BARCELONA, Spain, Sept. 6 -- An antiplatelet-anticoagulant duo, which showed promise in treating coronary disease, increased the risk of life-threatening bleeding events in patients with peripheral arterial disease, according to results of a trial reported here.
Four percent of patients randomized to Coumadin (warfarin) plus aspirin had life-threatening bleeding events versus 1.2% of patients treated with aspirin alone (P
The WAVE study recruited 2,161 patients and evenly randomized them to the Coumadin-plus-aspirin regimen or aspirin alone. The average age of patients was 64, and 74% were women. Twenty-nine percent of the participants were current smokers, and 81% had limb peripheral arterial disease. The average blood pressure in both arms was 137/78 mm Hg. At baseline, 98% of the participants were on antiplatelet therapy.
In each group treatment was titrated to reach International Normalization Ratio (INR) levels of 1.8 to 3.5.
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.